.jpg)
Curevo rounds up $110M to challenge GSK’s Shringrix, nabs Moncef Slaoui to lead board
In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former GSK leaders to its board.
In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former GSK leaders to its board.
